Literature DB >> 33423213

Higher Plasma Osteopontin Concentrations Associated with Subsequent Development of Chronic Shunt-Dependent Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage.

Reona Asada1, Yoshinari Nakatsuka1, Hideki Kanamaru1, Fumihiro Kawakita1, Masashi Fujimoto1, Yoichi Miura1, Masato Shiba1, Ryuta Yasuda1, Naoki Toma1, Hidenori Suzuki2.   

Abstract

A matricellular protein osteopontin (OPN) is considered to exert neuroprotective and healing effects on neurovascular injuries in an acute phase of aneurysmal subarachnoid hemorrhage (SAH). However, the relationships between OPN expression and chronic shunt-dependent hydrocephalus (SDHC) have never been investigated. In 166 SAH patients (derivation and validation cohorts, 110 and 56, respectively), plasma OPN levels were serially measured at days1-3, 4-6, 7-9, and 10-12 after aneurysmal obliteration. The OPN levels and clinical factors were compared between patients with and without subsequent development of chronic SDHC. Plasma OPN levels in the SDHC patients increased from days 1-3 to days 4-6 and remained high thereafter, while those in the non-SDHC patients peaked at days 4-6 and then decreased over time. Plasma OPN levels had no correlation with serum levels of C-reactive protein (CRP), a systemic inflammatory marker. Univariate analyses showed that age, modified Fisher grade, acute hydrocephalus, cerebrospinal fluid drainage, and OPN and CRP levels at days 10-12 were significantly different between patients with and without SDHC. Multivariate analyses revealed that higher plasma OPN levels at days 10-12 were an independent factor associated with the development of SDHC, in addition to a more frequent use of cerebrospinal fluid drainage and higher modified Fisher grade at admission. Plasma OPN levels at days 10-12 maintained similar discrimination power in the validation cohort and had good calibration on the Hosmer-Lemeshow goodness-of-fit test. Prolonged higher expression of OPN may contribute to the development of post-SAH SDHC, possibly by excessive repairing effects promoting fibrosis in the subarachnoid space.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Biomarker; Chronic hydrocephalus; Intracranial aneurysm; Osteopontin; Subarachnoid hemorrhage

Mesh:

Substances:

Year:  2021        PMID: 33423213     DOI: 10.1007/s12975-020-00886-x

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  4 in total

Review 1.  Potential roles of matricellular proteins in stroke.

Authors:  Fumihiro Kawakita; Hideki Kanamaru; Reona Asada; Hidenori Suzuki
Journal:  Exp Neurol       Date:  2019-09-06       Impact factor: 5.330

2.  Osteopontin induces atrial fibrosis by activating Akt/GSK-3β/β-catenin pathway and suppressing autophagy.

Authors:  Rongjie Lin; Shaohui Wu; Dan Zhu; Mu Qin; Xu Liu
Journal:  Life Sci       Date:  2020-01-15       Impact factor: 5.037

3.  Osteopontin enhances multi-walled carbon nanotube-triggered lung fibrosis by promoting TGF-β1 activation and myofibroblast differentiation.

Authors:  Jie Dong; Qiang Ma
Journal:  Part Fibre Toxicol       Date:  2017-06-08       Impact factor: 9.400

Review 4.  Hydrocephalus after Subarachnoid Hemorrhage: Pathophysiology, Diagnosis, and Treatment.

Authors:  Sheng Chen; Jinqi Luo; Cesar Reis; Anatol Manaenko; Jianmin Zhang
Journal:  Biomed Res Int       Date:  2017-03-08       Impact factor: 3.411

  4 in total
  2 in total

Review 1.  An Update on Antioxidative Stress Therapy Research for Early Brain Injury After Subarachnoid Hemorrhage.

Authors:  Fa Lin; Runting Li; Wen-Jun Tu; Yu Chen; Ke Wang; Xiaolin Chen; Jizong Zhao
Journal:  Front Aging Neurosci       Date:  2021-12-06       Impact factor: 5.750

2.  Risk factors for chronic hydrocephalus in patients with intracerebral hemorrhage complicated by coma after emergency hematoma removal.

Authors:  Hai-Tao Yuan; Jun Feng; Qian Wang
Journal:  Ann Transl Med       Date:  2022-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.